Reversing PD-1 Resistance in Advanced Melanoma: Insights from the SPOTLIGHT-203 Phase II Trial of BO-112 Plus Pembrolizumab
The SPOTLIGHT-203 Phase II trial demonstrates that intratumoral BO-112 combined with pembrolizumab shows promise by achieving a 25% ORR in anti-PD-1-resistant advanced melanoma with manageable safety, offering a potential new therapeutic avenue.